Goldman Sachs Upgrades Clovis Oncology To Buy

Analysts at Goldman Sachs upgraded

from Neutral to Buy. The price target for Clovis Oncology has been raised from $60 to $66. Clovis Oncology shares have jumped 40.93% over the past 52 weeks, while the S&P 500 index has gained 14.83% in the same period. Clovis Oncology shares gained 4.95% to $81.25 in pre-market trading.